Clinical development of atypical antipsychotics: Research design and evaluation

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 12, 1998, Pages 10-16

  Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE;

CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; CROSS-CULTURAL COMPARISON; DRUG ADMINISTRATION SCHEDULE; DRUG APPROVAL; DRUGS, INVESTIGATIONAL; EUROPE; FEMALE; HUMANS; MALE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RESEARCH DESIGN; SCHIZOPHRENIA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0031712843     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Arvanitis LA, Miller BG, and The Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997;42:233-246
2. Beasley CM Jr, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996;124:159-167
3. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-137
4. Beasley CM Jr, Tollefson GD, Tran PV, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
5. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-118
6. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
7. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
8. Kane JM, Honigfeld G, Singer J, et al. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 1988;24:62-67
9. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557
10. Peuskens J and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus halopendol. Br J Psychiatry 1995;166:712-726
11. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997;96:265-273
12. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15 (suppl 1):36S-44S
13. Borison RL, Arvanitis LA, Miller BG, et al. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-169
14. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
15. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
16. van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996;124:167-175
17. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-791
18. Bakke OM, Manocchia M, de Abajo F, et al. Drug safety discontinuations in the UK, the US, and Spain, 1974-1993: a regulatory perspective. Clinical Pharmacology and Therapeutics 1995;58:108-117
19. Drummond M. The emerging government requirement for economic evaluation of pharmaceuticals. Pharmacoeconomics 1994;6( suppl 1): 42-50
20. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1997
21. Risperdal [package insert]. Titusville, NJ: Janssen Pharmaceutica; 1998
22. Schreiber JL, Breier A, Pickar D. Characteristics of patients selected for treatment on a schizophrenia research unit. Hosp Community Psychiatry 1990;41:441-443
23. Van Putten T, Marder SR, Mintz JA. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990;47:754-758
24. Angst J, Bech P, Bobon D, et al. Report on the Third Consensus Conference on the Methodology of Clinical Trials With Antipsychotic Drugs. Pharmacopsychiatry 1991;24:149-152
25. Johnson AL, Johnson DAW. Peer review of "Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol." Br J Psychiatry 1995;166:727-733